Neola Medical AB will participate in BioStock’s investor event “Investing in Life Science – From Seed to Success” in Stockholm on September 22, 2026.
CEO Hanna Sjöström will present Neola Medical’s latest progress and strategic priorities, including the recently granted FDA Breakthrough Device Designation for Neola®, and outline the company’s continued development toward the U.S. market.
The presentation will take place at 09:45 CET at IVA Konferens, Grev Turegatan 16, Stockholm.
“Following the FDA Breakthrough Device Designation, we are entering an important phase for Neola Medical. I look forward to meeting investors in Stockholm and sharing more about our recent progress, our sharpened clinical and regulatory strategy, and the next steps toward bringing Neola® to neonatal intensive care,” says Hanna Sjöström, CEO of Neola Medical.
